Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 34

Sort by

Sort Order Select

Journal Articles

Sequential Chemotherapy and Blinatumomab to Improve Minimal Residual Disease in Adult Ph- B-Lineage Acute Lymphoblastic Leukemia. Final Results of the Phase II Gimema LAL2317 Trial

Blood (2023) 142 (Supplement 1): 826.

https://doi.org/10.1182/blood-2023-174973

Published: 2023

Journal Articles

36-Month Follow-up Results of the Gimema ‘Veritas’ Trial of Front-Line Venetoclax and Rituximab (VenR) in Young and Fit Patients with Chronic Lymphocytic Leukemia and an Adverse Biologic Profile

Blood (2023) 142 (Supplement 1): 1905.

https://doi.org/10.1182/blood-2023-181597

Published: 2023

Journal Articles

Clinical Features and Treatment Response in Patients with Multiple Myeloma and CD20 Expression: Real-Life Experience of the Centro-Italy Multiple Myeloma Macroregional District

Blood (2022) 140 (Supplement 1): 12549–12550.

https://doi.org/10.1182/blood-2022-166464

Published: 2022

Journal Articles

Gimema ALL2418: Interim Analysis of a Phase Iia Study of Feasibility and Effectiveness of Inotuzumab Ozogamicin in Adult Patients with B-Cell Acute Lymphoblastic Leukemia with Positive Minimal Residual Disease before Any Hematopoietic Stem Cell Transplantation

Blood (2022) 140 (Supplement 1): 6119–6121.

https://doi.org/10.1182/blood-2022-157937

Published: 2022

Journal Articles

Dissecting Ph-like ALL: The Role of Genomic Lesion and Minimal Residual Disease in Refining Outcome

Deborah Cardinali, Irene Della Starza, Vittorio Bellomarino, Marco Beldinanzi, Mariangela Di Trani, Felicetto Ferrara, Monica Bocchia, Prassede Salutari, Monia Lunghi, Erika Borlenghi, Matteo Piccini, Catello Califano, Alfonso Piciocchi, Maria Stefania De Propris, Robin Foà, Sabina Chiaretti

Blood (2022) 140 (Supplement 1): 6350–6351.

https://doi.org/10.1182/blood-2022-163559

Published: 2022

Journal Articles

Host immune system modulation in Ph + acute lymphoblastic leukemia patients treated with dasatinib and blinatumomab

Maria Cristina Puzzolo, Giulia Radice, Nadia Peragine, Maria Stefania de Propris, Paola Mariglia, Marco Vignetti, Antonella Vitale, Renato Bassan, Mario Annunziata, Gianluca Gaidano, Alessandro Rambaldi, Sabina Chiaretti, Anna Guarini, Robin Foà

Blood (2021) 138 (22): 2290–2293.

https://doi.org/10.1182/blood.2021011822

Published: 2021

Includes: Supplemental data

Journal Articles

Efficacy and Safety of Front-Line Venetoclax and Rituximab (VenR) for the Treatment of Young Patients with Chronic Lymphocytic Leukemia and an Unfavorable Biologic Profile. Preliminary Results of the Gimema Study 'Veritas'

Francesca Romana Mauro, MD PhD, Gianluigi Reda, MD, Valentina Arena, MS, Livio Trentin, MD, Marta Coscia, MD PhD, Paolo Sportoletti, MD, Luca Laurenti, MD, Gianluca Gaidano, Roberto Marasca, MD, Lorella Orsucci, MD, Roberta Murru, MD, Caterina Stelitano, Fiorella Ilariucci, MD, Donato Mannina, MD, Massimo Massaia, MD, Gian Matteo Rigolin, Lydia Scarfo, Monia Marchetti, MD, Luciano Levato, MD, Monica Tani, MD, Annalisa Arcari, MD, Gerardo Musuraca, MD, Marina Deodato, Piero Galieni, Catello Califano, MD, Daniela Gottardi, MD, Anna Marina Liberati, MD, Daniela Pietrasanta, MD, Stefano Molica, MD, Ramona Cassin, MD, Andrea Visentin, MDPhD, Candida Vitale, MDPhD, Gianfranco Lapietra, MD, Irene Della Starza, PhD, Maria Stefania De Propris, PhD, Sara Raponi, PhD, Mauro Nanni, PhD, Ilaria Del Giudice, MD PhD, Giorgia Giuliani, PhD, Marco Vignetti, MD, Anna Guarini, PhD, Francesco Albano, Antonino Neri, MD, Antonio Cuneo, MD, Robin Foà, MD

Blood (2020) 136 (Supplement 1): 47–49.

https://doi.org/10.1182/blood-2020-135922

Published: 2020

Journal Articles

Role of Blinatumomab in Minimal Residual Disease and Hematologic Relapsed/Refractory Adult Acute Lymphoblastic Leukemia Patients Treated over 5 Years. a Single Center Experience

Michela Ansuinelli, MD, Antonella Vitale, MD, Giovanna Pecoraro, MD, Saveria Capria, MD, Silvia Maria Trisolini, MD, Clara Minotti, MD, Claudio Cartoni, MD, Anna Maria Testi, MD, Maria Luisa Moleti, MD, Anna Paola Iori, MD, Walter Barberi, MD PhD, Irene Della Starza, PhD, Loredana Elia, Bs, Francesca Mancini, Maria Stefania De Propris, Anna Guarini, PhD, Sabina Chiaretti, MD PhD, Robin Foà, MD

Blood (2019) 134 (Supplement_1): 5121.

https://doi.org/10.1182/blood-2019-128156

Published: 2019

Journal Articles

TP53 Clonal and Subclonal Architecture in Chronic Lymphocytic Leukemia Patients Under Ibrutinib Treatment

Ilaria Del Giudice, Luciana Cafforio, Luca Vincenzo Cappelli, MD, Caterina Ilari, PhD, Sara Raponi, Maria Stefania De Propris, Paola Mariglia, Francesca Romana Mauro, Marco Vignetti, Anna Guarini, PhD, Robin Foà, MD

Blood (2018) 132 (Supplement 1): 3119.

https://doi.org/10.1182/blood-2018-99-114232

Published: 2018

Journal Articles

Fludarabine, Cyclophosphamide, Ofatumumab (FC-O2) As Front-Line Treatment for Young and Fit Patients with Chronic Lymphocytic Leukemia (CLL): Preliminary Results of the Prospective Phase 2 LLC0911 Gimema Study

Blood (2015) 126 (23): 2946.

https://doi.org/10.1182/blood.V126.23.2946.2946

Published: 2015

Journal Articles

Acute Myeloid Leukemia Patients with an Undefined Genetic Profile at Diagnosis: Clinical and Prognostic Aspects

Blood (2014) 124 (21): 5326.

https://doi.org/10.1182/blood.V124.21.5326.5326

Published: 2014

Journal Articles

Role of CD133 As a Marker of Previous Myelodysplasia in De Novo Elderly Patients with Acute Myeloid Leukemia

Blood (2014) 124 (21): 1063.

https://doi.org/10.1182/blood.V124.21.1063.1063

Published: 2014

Journal Articles

Independent Prognostic Impact of CD15 for Achievement of Complete Remission in Patients with Acute Myeloid Leukemia

Blood (2014) 124 (21): 3687.

https://doi.org/10.1182/blood.V124.21.3687.3687

Published: 2014

Journal Articles

Expanded Natural Killer Cells For The Control Of Minimal Residual Disease In Ph+ Acute Lymphoblastic Leukemia Patients

Giovanni Fernando Torelli, MD, Nadia Peragine, PhD, Sara Raponi, PhD, Paola Mariglia, BS, Simona Pauselli, MD, Maria Stefania De Propris, PhD, Antonella Vitale, Anna Guarini, Robin Foá, MD

Blood (2013) 122 (21): 2026.

https://doi.org/10.1182/blood.V122.21.2026.2026

Published: 2013

Journal Articles

Cellular Composition and Clonal Evolution of 295 Type III PNH Clones: An Italian Multi-Laboratory Study

Blood (2012) 120 (21): 3482.

https://doi.org/10.1182/blood.V120.21.3482.3482

Published: 2012

Journal Articles

Selective Splenic Artery Embolization for the Treatment of Thrombocytopenia and Hypersplenism in Paroxysmal Nocturnal Hemoglobinuria (PNH)

Anna Paola Iori, Karen Brown, David J. Araten, Emilia Scalzulli, Giovanni Fernando Torelli, Maria Stefania De Propris, Corrado Girmenia, Filippo Maria Salvatori, Orly Zelig, Robin Foa, MD, Lucio Luzzatto

Blood (2012) 120 (21): 4408.

https://doi.org/10.1182/blood.V120.21.4408.4408

Published: 2012

Journal Articles

Dasatinib as first-line treatment for adult patients with Philadelphia chromosome–positive acute lymphoblastic leukemia

Blood (2011) 118 (25): 6521–6528.

https://doi.org/10.1182/blood-2011-05-351403

Published: 2011

Journal Articles

Rituximab Plus Chlorambucil As Initial Treatment for Elderly Patients with Chronic Lymphocytic Leukemia (CLL): Effect of Pre-Treatment Biological Characteristics and Gene Expression Patterns on Response to Treatment

Blood (2011) 118 (21): 294.

https://doi.org/10.1182/blood.V118.21.294.294

Published: 2011

Journal Articles

A Phase II Study of Chlorambucil Plus Rituximab Followed by Maintenance Versus Observation In Elderly Patients with Previously Untreated Chronic Lymphocytic Leukemia: Results of the First Interim Analysis

Blood (2010) 116 (21): 2462.

https://doi.org/10.1182/blood.V116.21.2462.2462

Published: 2010

Journal Articles

Distribution of Genetic and Molecular Prognostic Markers in Young Patients with Chronic Lymphocytic Leukemia (CLL) in Different Phases of the Disease.

Ilaria Del Giudice, Francesca Romana Mauro, Mauro Nanni, Rita Barzotti, Maria Stefania De Propris, Sara Raponi, Simona Santangelo, Marilisa Marinelli, Nadia Peragine, Daniele Armiento, Francesca Paoloni, Anna Guarini, Robin Foà

Blood (2009) 114 (22): 4373.

https://doi.org/10.1182/blood.V114.22.4373.4373

Published: 2009

NARROW

Sequential Chemotherapy and Blinatumomab to Improve Minimal Residual Disease in Adult Ph- B-Lineage Acute Lymphoblastic Leukemia. Final Results of the Phase II Gimema LAL2317 Trial

36-Month Follow-up Results of the Gimema ‘Veritas’ Trial of Front-Line Venetoclax and Rituximab (VenR) in Young and Fit Patients with Chronic Lymphocytic Leukemia and an Adverse Biologic Profile

Clinical Features and Treatment Response in Patients with Multiple Myeloma and CD20 Expression: Real-Life Experience of the Centro-Italy Multiple Myeloma Macroregional District

Gimema ALL2418: Interim Analysis of a Phase Iia Study of Feasibility and Effectiveness of Inotuzumab Ozogamicin in Adult Patients with B-Cell Acute Lymphoblastic Leukemia with Positive Minimal Residual Disease before Any Hematopoietic Stem Cell Transplantation

Dissecting Ph-like ALL: The Role of Genomic Lesion and Minimal Residual Disease in Refining Outcome

Host immune system modulation in Ph + acute lymphoblastic leukemia patients treated with dasatinib and blinatumomab

Efficacy and Safety of Front-Line Venetoclax and Rituximab (VenR) for the Treatment of Young Patients with Chronic Lymphocytic Leukemia and an Unfavorable Biologic Profile. Preliminary Results of the Gimema Study 'Veritas'

Role of Blinatumomab in Minimal Residual Disease and Hematologic Relapsed/Refractory Adult Acute Lymphoblastic Leukemia Patients Treated over 5 Years. a Single Center Experience

TP53 Clonal and Subclonal Architecture in Chronic Lymphocytic Leukemia Patients Under Ibrutinib Treatment

Fludarabine, Cyclophosphamide, Ofatumumab (FC-O2) As Front-Line Treatment for Young and Fit Patients with Chronic Lymphocytic Leukemia (CLL): Preliminary Results of the Prospective Phase 2 LLC0911 Gimema Study

Acute Myeloid Leukemia Patients with an Undefined Genetic Profile at Diagnosis: Clinical and Prognostic Aspects

Role of CD133 As a Marker of Previous Myelodysplasia in De Novo Elderly Patients with Acute Myeloid Leukemia

Independent Prognostic Impact of CD15 for Achievement of Complete Remission in Patients with Acute Myeloid Leukemia

Expanded Natural Killer Cells For The Control Of Minimal Residual Disease In Ph+ Acute Lymphoblastic Leukemia Patients

Cellular Composition and Clonal Evolution of 295 Type III PNH Clones: An Italian Multi-Laboratory Study

Selective Splenic Artery Embolization for the Treatment of Thrombocytopenia and Hypersplenism in Paroxysmal Nocturnal Hemoglobinuria (PNH)

Dasatinib as first-line treatment for adult patients with Philadelphia chromosome–positive acute lymphoblastic leukemia

Rituximab Plus Chlorambucil As Initial Treatment for Elderly Patients with Chronic Lymphocytic Leukemia (CLL): Effect of Pre-Treatment Biological Characteristics and Gene Expression Patterns on Response to Treatment

A Phase II Study of Chlorambucil Plus Rituximab Followed by Maintenance Versus Observation In Elderly Patients with Previously Untreated Chronic Lymphocytic Leukemia: Results of the First Interim Analysis

Distribution of Genetic and Molecular Prognostic Markers in Young Patients with Chronic Lymphocytic Leukemia (CLL) in Different Phases of the Disease.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only